Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330902
Status:
COMPLETED
Last Update Posted:
2007-10-31
First Post:
2006-05-25
Brief Title:
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density PFalciparum Parasitaemia in Sudan
Sponsor:
London School of Hygiene and Tropical Medicine
Organization:
London School of Hygiene and Tropical Medicine
Study Overview
Official Title:
Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate SPAS Versus SPAS Plus Primaquine for Clearance of Low Density P Falciparum Infection in Eastern Sudan
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In areas of seasonal malaria transmission treatment of carriers of malaria parasites whose parasitaemia persists at very low levels throughout the dry season could be a useful strategy for malaria control in areas with a short transmission season We did a randomized trial to compare two regimens for clearance of low level parasitaemia in the dry season
Detailed Description:
104 individuals with low density Plasmodium falciparum infection detected by polymerase chain reaction PCR were randomized to receive sulfadoxine-pyrimethamine and three daily doses of artesunate SPAS or SPAS and a dose of primaquine SPASPQ and were followed up for 14 days during the transmission-free season in Eastern Sudan Subjects were visited on days 3 7 and 14 after the start of treatment to record any adverse events and to detect Pfalciparum using PCR PCR positive samples were tested for gametocytes using RT-PCR Packed cell volume was measured on days 7 and 14
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None